Abstract
BackgroundNon-invasive tumor blood flow (TBF) quantification is a candidate approach for risk stratification and monitoring of prostate cancer patients. Validation data have recently been published on prostate TBF measurement with the widely used positron emission tomography (PET) flow tracer 82Rubidium (82Rb). However, no test-retest data is available for TBF measurement with 82Rb PET in prostate cancer. Such information is important to determine the potential clinical usefulness of the technique. The aim of the present study was to determine the test-retest repeatability of TBF measurement with both dynamic and static 82Rb PET.MethodsWe recruited 10 low-to-high-risk prostate cancer patients scheduled for clinical prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) or magnetic resonance imaging. Pelvic and cardiac static and dynamic 82Rb PET/CT were performed at baseline and repeated on a different day within 1 week. In total, 11 primary lesions were analyzed.ResultsFor K1, standardized uptake values (SUV)max, SUVmean, and SUVpeak, prostate cancer 82Rb PET TBF has a repeatability of 32%, 51%, 53%, and 58% and an intraclass correlation of 0.98, 0.89, 0.88, and 0.88, respectively.ConclusionDynamic 82Rb PET/CT with kinetic modeling measures TBF in prostate cancer with high repeatability, which allows identification of blood flow changes of 32%. Static late-uptake 82Rb PET/CT is inferior, and only intra-individual blood flow changes above 51% can hence be recognized.
Highlights
Non-invasive tumor blood flow (TBF) quantification is a candidate approach for risk stratification and monitoring of prostate cancer patients
The dynamic and static TBF measurements of test and retest scans are shown in Table 1 for volumes of interest (VOIs) drawn from prostate-specific membrane antigen (PSMA) standardized uptake values (SUV) 6 fixed threshold
The main findings of the present study are that the repeatability of TBF measurement was approximately 32% for dynamic 82Rb positron emission tomography (PET)/computed tomography (CT) and 51–58% for static 82Rb PET/CT depending on the SUV measure used
Summary
Non-invasive tumor blood flow (TBF) quantification is a candidate approach for risk stratification and monitoring of prostate cancer patients. No test-retest data is available for TBF measurement with 82Rb PET in prostate cancer. Such information is important to determine the potential clinical usefulness of the technique. The aim of the present study was to determine the test-retest repeatability of TBF measurement with both dynamic and static 82Rb PET. Tumor blood flow (TBF) imaging has previously been studied for characterization and treatment response evaluation in various cancers, including nonsmall cell lung cancer [2, 3], breast cancer [4,5,6,7], head and neck cancer [8], colorectal cancer [3, 9], brain cancer [10], and prostate cancer [11,12,13]. The aim of the present study was to evaluate the repeatability of TBF measurement with static and dynamic 82Rb PET
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
